No label defined (Q3204678)

From EU Knowledge Graph
Revision as of 08:04, 14 October 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): Our group has developed the methodology to generate artificial lipid nanoparticles that resemble natural exosomes by attaching them TRAIL on their surface (LUV-TRAIL) and has demonstrated their greater anti-tumoral activity compared to the soluble form of TRAIL both in haematological neoplasms and in solid tumors (lung, breast and colon). Despite this, in some of the cancers studied, LUV-TRAIL-induced death rates have not been very high. This in...)
Jump to navigation Jump to search
Project Q3204678 in Spain
Language Label Description Also known as
English
No label defined
Project Q3204678 in Spain

    Statements

    0 references
    29,250.0 Euro
    0 references
    58,500.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2017
    0 references
    31 March 2020
    0 references
    INSTITUTO DE INVESTIGACION SANITARIA ARAGON
    0 references

    41°39'7.67"N, 0°52'51.38"W
    0 references
    50297
    0 references
    Nuestro grupo ha desarrollado la metodología para generar nanopartículas lipídicas artificiales que asemejan a los exosomas naturales acoplándoles TRAIL en su superficie (LUV-TRAIL) y ha demostrado su mayor actividad anti-tumoral en comparación con la forma soluble de TRAIL tanto en neoplasias hematológicas como en tumores sólidos (pulmón, mama y colon). A pesar de ello, en algunos de los cánceres estudiados, los porcentajes de muerte inducida por los LUV-TRAIL no han sido muy elevados. Esto indica que aunque estas células presentan resistencia a TRAIL soluble, pueden terminar siendo sensibles al menos parcialmente a este ligando mortal cuando el estímulo apoptótico es potenciado como en el caso del trasmitido por los LUV-TRAIL. Este proyecto de carácter traslacional pretende optimizar los LUV-TRAIL ya generados a través de distintas aproximaciones experimentales para conseguir aumentar su citotoxicidad y/o especificidad y llevar a cabo su validación preclínica, algo absolutamente necesario para conseguir llevar esta nueva formulación a la clínica. El modelo experimental tumoral elegido para llevar a cabo el proyecto propuesto, es el sarcoma. Un conjunto de tumores raros en los que es necesario explorar nuevas aproximaciones terapéuticas para mejorar la supervivencia, en los que la capacidad anti-tumoral de TRAIL todavía poco explorada muestra que en general son tumores relativamente resistentes a TRAIL soluble a pesar de lo cual existen datos en pacientes tratados con formulaciones basadas en TRAIL que apuntan a que éste puede ser efectivo como tratamiento frente a determinados sarcomas. (Spanish)
    0 references
    Our group has developed the methodology to generate artificial lipid nanoparticles that resemble natural exosomes by attaching them TRAIL on their surface (LUV-TRAIL) and has demonstrated their greater anti-tumoral activity compared to the soluble form of TRAIL both in haematological neoplasms and in solid tumors (lung, breast and colon). Despite this, in some of the cancers studied, LUV-TRAIL-induced death rates have not been very high. This indicates that although these cells have soluble TRAIL resistance, they may end up being sensitive at least partially to this deadly ligand when the apoptotic stimulus is enhanced as in the case of LUV-TRAIL transmitted. This translational project aims to optimise the LUV-TRAIL already generated through different experimental approaches to increase their cytotoxicity or specificity and carry out their preclinical validation, something absolutely necessary to get this new formulation to the clinic. The experimental tumor model chosen to carry out the proposed project is sarcoma. A set of rare tumors in which it is necessary to explore new therapeutic approaches to improve survival, in which the anti-tumoral capacity of TRAIL still underexplored shows that in general they are relatively resistant to soluble TRAIL although there are data in patients treated with TRAIL-based formulations that suggest that it can be effective as a treatment against certain sarcomas. (English)
    14 October 2021
    0 references
    Zaragoza
    0 references

    Identifiers

    PI16_00526
    0 references